F-18 FLT shows promise for antiangiogenic therapy assessment

08/8/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine evaluated three F-18 labeled PET tracers with axitinib for assessment of antiangiogenic therapy response. Researchers conducted PET scans in mice with heterogeneous glioma and breast ductal carcinoma using PET tracers F-18 FDG, F-18 FLT and F-18 FtRGD, finding F-18 FLT allowed overall earlier detection of the therapeutic response, but each agent had different strengths. "These data suggest that differences in tumor biology may be critical for individual patient management and the choice of radiopharmaceutical agents for the noninvasive monitoring of therapy efficacy," the authors wrote.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI